For 2015 the consensus of the earnings per share of Galapagos is at loss of 1,13 euros. Based on this the price/earnings-ratio equals -35,54.
For this year the analysts don't expect Galapagos to pay any dividends. 0On average the stocks in this sector yield a dividend return of around 0,22 percent.
The stocks MDxHealth, IBA and Ablynx in the sector biotech sector have the most buy recommendations. The 3 most recent recommendations for the biotech sector were provided by Credit Suisse (hold, 50,00 euros), DeGroof Petercam (buy, 60,00 euros) and Goldman Sachs (hold, 56,00 euros).
Galapagos's book value/price equals 0,17. The biotech company now trades at a Shiller PE of 1.36. The stock now trades at 40,16 euros. This equals 32 times the 2014's earnings per share.